Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 308 results for breast cancer

  1. Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)

    Evidence-based recommendations on breast reconstruction using lipomodelling after breast cancer treatment. This involves taking fat from the abdomen or thighs and injecting it into the breast in the area of the deformity caused by surgery.

    Interventional procedures guidance
    Published
    23 January 2012
    View recommendations

    Sections for IPG417

  2. Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)

    Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).

    Interventional procedures guidance
    Published
    22 April 2009
    View recommendations

    Sections for IPG296

  3. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

    Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.

    Technology appraisal guidance
    Published
    24 October 2012
    View recommendations

    Sections for TA265

  4. Artificial intelligence technologies for mammography: early value assessment

    Awaiting development Reference number: GID-HTE10062 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  5. Interstitial laser therapy for breast cancer (IPG89)

    Evidence-based recommendations on interstitial laser therapy for breast cancer. This involves using laser energy to destroying the cancer cells.

    Interventional procedures guidance
    Published
    22 September 2004
    View recommendations

    Sections for IPG89

  6. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  7. Endoscopic axillary lymph node retrieval for breast cancer (IPG147)

    Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer. This involves using narrow instruments to remove the lymph nodes through small, rather than large, openings to reduce the risk of infection and other problems.

    Interventional procedures guidance
    Published
    14 December 2005
    View recommendations

    Sections for IPG147

  8. Suspected cancer: recognition and referral (NG12)

    This guideline covers identifying children, young people and adults with symptoms that could be caused by cancer. It outlines appropriate investigations in primary care, and selection of people to refer for a specialist opinion. It aims to help people understand what to expect if they have symptoms that may suggest cancer.

    NICE guideline
    Last updated
    1 May 2025

    Sections for NG12

  9. Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

    Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.

    Interventional procedures guidance
    Published
    23 July 2008
    View recommendations

    Sections for IPG268

  10. Chemoprevention to reduce incidence of breast cancer:- A randomised controlled trial is recommended to compare the clinical and cost effectiveness of aromatase inhibitors and tamoxifen for reducing the incidence of breast cancer in women with a family history of breast or ovarian cancer. [new 2013]

    CG164/4 Question Chemoprevention to reduce incidence of breast cancer:- A randomised controlled trial is recommended to compare the...

    Research recommendation
    Published
    9 June 2015

  11. Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]

    Awaiting development Reference number: GID-TA11565 Expected publication date:  21 May 2026

    Technology appraisal guidance
    Awaiting development

  12. Women with breast cancer:- What is the safety and effectiveness of alternatives to systemic HRT as treatments for menopausal symptoms in women who have had treatment for breast cancer?

    Recommendation ID NG23/1 Question Women with breast cancer:- What is the safety and effectiveness of alternatives to systemic HRT as...

    Research recommendation
    Published
    11 December 2015

  13. Effects of HRT on breast cancer risk:- What is the difference in the risk of breast cancer in menopausal women on HRT with progesterone, progestogen or selective oestrogen receptor modulators?

    NG23/2 Question Effects of HRT on breast cancer risk:- What is the difference in the risk of breast cancer in menopausal...

    Research recommendation
    Published
    11 December 2015

  14. Surgery to the breast:- What is the optimum tumour-free margin width after breast-conserving surgery for women with ductal carcinoma in situ (DCIS) and invasive breast cancer?

    NG101/1 Question Surgery to the breast:- What is the optimum tumour-free margin width after breast-conserving surgery for...

    Research recommendation
    Published
    11 December 2018

  15. Guidance, NICE advice and quality standards in development

    View a complete list of all our guidance, NICE advice and quality standards currently in development